333
We analyzed the incidence of DVT in 232 MM patients who received a combination of chemotherapy and thalidomide on 2 protocols that differed only by the inclusion of doxorubicin in one.
 232 MM patients: Subject; 232: Subject.Population; DVT: Effect; chemotherapy: Treatment; thalidomide: Treatment; MM: Treatment.Disorder; chemotherapy: Treatment.Drug; thalidomide: Treatment.Drug; chemotherapy: Combination.Drug; thalidomide: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 232 MM patients: Subject; 232: Subject.Population; DVT: Effect; chemotherapy: Treatment; thalidomide: Treatment; MM: Treatment.Disorder; chemotherapy: Treatment.Drug; thalidomide: Treatment.Drug; chemotherapy: Combination.Drug; thalidomide: Combination.Drug